Amgen Inc. vs The Coca-Cola Company: Strategic Comparison

This in-depth comparison examines Amgen Inc. and The Coca-Cola Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Amgen Inc. on its own, evaluating The Coca-Cola Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Amgen Inc. and The Coca-Cola Company is widest.

On the headline numbers, Amgen Inc. reports annual revenue of $36.8B against $47.9B for The Coca-Cola Company, while their respective market capitalizations stand at $228.2B and $379.0B. Both Amgen Inc. and The Coca-Cola Company are headquartered in United States, so they compete in a shared home market and regulatory environment.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

The Coca-Cola Company: The Coca-Cola Company (NYSE: KO), headquartered in Atlanta, is the world's largest nonalcoholic beverage company. It owns more than 200 brands, including Coca-Cola, Sprite, Fanta, Smartwater, Powerade, Minute Maid, Costa Coffee, BodyArmor and fairlife. For the most part it does not bottle its own drinks. It owns the trademarks and formulas, runs global marketing, and sells concentrate to a network of bottling partners that make and distribute finished beverages in more than 200 countries and territories. The company reported $47.9 billion in 2025 revenue and had about 65,900 employees at year-end. Henrique Braun has been CEO since March 31, 2026.

Amgen Inc. and The Coca-Cola Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Amgen Inc. and The Coca-Cola Company.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

The Coca-Cola Company business model: Coca-Cola runs a franchise model. The company develops or acquires beverage recipes and runs global marketing, including sponsorships such as the Olympics. It earns revenue by selling concentrate to independent bottling companies around the world, such as Coca-Cola Europacific Partners. The bottlers add water, package the drinks and handle distribution, and pay Coca-Cola for the right to sell its brands.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Amgen Inc. stack up against those of The Coca-Cola Company.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

The Coca-Cola Company competitive advantage: Coca-Cola's advantage is its brand and its distribution network. Its products reach even very remote places through a system of bottlers, trucks and independent shopkeepers that took more than a century to build. A new drinks company can develop a product people like, but it cannot quickly match Coca-Cola's reach into shops and refrigerators worldwide.

Future prospects matter as much as current results. The growth strategies below explain how Amgen Inc. and The Coca-Cola Company each plan to expand from here.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

The Coca-Cola Company growth strategy: Coca-Cola calls itself a 'total beverage company': it keeps trademark Coca-Cola and Coca-Cola Zero Sugar at the center while building scale in coffee (Costa), sports hydration (BodyArmor, Powerade), premium water (Smartwater, Topo Chico) and value-added dairy (fairlife). Revenue growth management, meaning pack sizes, price tiers and mini-cans tuned to each market, is the main lever for growth without heavy volume gains. Alcohol-adjacent ready-to-drink products such as Jack Daniel's & Coca-Cola are produced with partners rather than on Coca-Cola's own books. The company also keeps refranchising bottlers: in October 2025 it agreed to sell a 41.52% stake in Coca-Cola Beverages Africa to Coca-Cola HBC for about $1.3 billion, a deal targeted to close by the end of 2026. In January 2026 it reportedly dropped a plan to sell Costa Coffee after private-equity bids fell short of its price.

A closer look at the financial trajectory of Amgen Inc. and The Coca-Cola Company rounds out the comparison.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.

The Coca-Cola Company: Coca-Cola's financial profile comes from its asset-light franchise model. It sells concentrates and syrups to independent bottlers, which own the capital-intensive plants, trucks and coolers, so the parent company keeps high margins on a relatively small asset base. FY2025 revenue was $47.941 billion with $13.107 billion in net income, up from $47.061 billion in revenue in 2024. In Q2 2026, net revenue grew 7% to $13.4 billion and comparable EPS rose 11% to $0.97. That cash supports the dividend: in February 2026 the board approved a 64th consecutive annual increase, to $0.53 per quarter. Berkshire Hathaway has held 400 million shares since the early 1990s, making it the largest single shareholder.